Corporate ActionJun 17, 2026, 09:23 PM
Legend Biotech Prices Public Offering of 7.7M ADSs at $29.35
AI Summary
Legend Biotech Corporation announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares (ADSs) at $29.35 per ADS. Each ADS represents two ordinary shares. The company expects gross proceeds of approximately $226 million, before deducting underwriting discounts and commissions and estimated offering expenses. Underwriters have a 30-day option to purchase up to an additional 1,155,000 ADSs. The offering is anticipated to close on June 23, 2026, with Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities serving as joint book-running managers.
Key Highlights
- Legend Biotech priced an underwritten public offering of 7,700,000 American Depositary Shares (ADSs).
- The public offering price is $29.35 per ADS.
- Each ADS represents two ordinary shares of the company.
- Gross proceeds are expected to be approximately $226 million, before deductions.
- Underwriters have a 30-day option to purchase up to an additional 1,155,000 ADSs.
- The offering is expected to close on June 23, 2026.
Price Impact
More from LEGN